A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity

NCT01776723

Version 15

October 28, 2016
TITLE: A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity

Sponsor: H. Lee Moffitt Cancer Center & Research Institute

Funding: INCYTE

*Principal Investigator: Eric Padron, MD
H. Lee Moffitt Cancer Center & Research Institute
12902 Magnolia Drive
Tampa, FL 33612
Telephone: 813-745-8264
e-mail address: Eric.Padron@moffitt.org

Co-Investigators: Rami Komrokji, MD
Alan F List, MD
Jeffrey E Lancet, MD
Kendra Sweet, MD
Bijal Shah, MD
Maria Balasis, BS
Qing Zhang

Statistician: Jae K. Lee, PhD

Version: 15
Date: 10/28/2016
Protocol Synopsis

**Title:** A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the treatment of Chronic Myelomonocytic Leukemia (CMML)

**Primary Objectives:**
1. To determine the safety and tolerability of ruxolitinib in CMML subjects at diagnosis or relapse. (phase I)
2. To determine overall best response rates as measured by the international working group criteria (2006). (phase II)

**Secondary Objectives:**
1. To determine the time to AML transformation of subjects on Ruxolitinib.
2. To determine the median overall survival.
3. To determine the duration of response.
4. To determine the change in symptom score from baseline to best response.
5. To determine the change in spleen length at 16 weeks.
6. To determine the change in downstream targets of JAK2 on ruxolitinib.
7. To determine if the in vitro activity of ruxolitinib correlates to response rates.
8. To determine if a correlation exist between the presence of the known recurrent mutations (JAK2, c-CBL, N-RAS, K-RAS, RUNX-1, TET2, SRSF2, EZH2, ASXL1, and DNMT3a) and response to ruxolitinib.
9. To determine non-V617F JAK2 mutations at end of study or progression and their clinical relevance in the context of ruxolitinib.

**Study Endpoints**

**Primary**
1. The maximum tolerated dose (MTD) of ruxolitinib for the treatment of CMML. The MTD is defined as the highest dose where less than 33% of subjects experience a drug related predefined dose limited toxicity (DLT).
2. Proportion of subject achieving a hematological response, partial response, complete response, or stable disease by the IWG 2006 criteria (see appendix B)

**Secondary**
3. Acute myeloid leukemia (AML) transformation according to WHO criteria.
4. Overall survival (OS).
5. Duration of response.
6. The Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF) at baseline and at best response.
7. >50% decrease in splenic length as measured by physical exam if applicable.
8. The suppression of pSTAT5 intracellular signaling after ruxolitinib in CMML subjects (pretreatment, at 1-2hr post treatment, cycle 2, cycle 4, and progression.)
9. Determine number of colonies formed in the presence of GM-CSF and/or ruxolitinib (pretreatment and progression) as a future predictor of response.
10. Mutational status in our CMML subjects by sanger sequencing of JAK2, c-CBL, N-RAS, K-RAS, RUNX-1, TET2, SRSF2, EZH2, ASXL1, and DNMT3a (pretreatment and progression).
11. Mutational status of JAK2 tyrosine kinase at time of progression by deep sequencing of JAK2 to include M929I, Y931C, G935R, R938L, 1960V, E985K. (pretreatment and at progression)

**Eligibility Criteria**

**Inclusion Criteria:**
1. Confirmed diagnosis of CMML using the World Health Organization (WHO)
2. Age >18 years at the time of obtaining informed consent.
3. Must be able to adhere to the study visit schedule and other protocol requirements.
4. Subjects must be able to provide adequate BM aspirate and biopsy specimens for histopathological analysis and standard cytogenetic analysis during the screening procedure.
5. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 is required.
6. Women of childbearing potential must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device [IUD], hormonal [birth control pills, injections, or implants], tubal ligation, partner’s vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap).
7. Must understand and voluntarily sign an informed consent form.
8. Must have a life expectancy of greater than 3 months at time of screening.

**Exclusion Criteria:**
1. Any of the following lab abnormalities:
   - Platelet count of less than 35,000/uL
   - Absolute Neutrophil Count (ANC) less than 250/uL
   - Serum Creatinine ≥ 2.0
   - Serum total bilirubin >1.5x ULN
2. Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of CMML within 28 days of the first day of study drug treatment.
3. Prior history of metastatic malignancy in past 2 years
4. Any serious medical condition or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he/she participates in the study.
5. Concurrent use of GM-CSF. G-CSF could be used for the short-term management of neutropenic infection. Stable doses of erythropoietin stimulating agents that were started >8 weeks from first ruxolitinib dose or corticosteroids that were being administered prior to screening are allowed.
6. Uncontrolled current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
7. Pregnant women are excluded from this study because ruxolitinib has not been studied in pregnant subjects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ruxolitinib, breastfeeding should be discontinued if the mother is treated with ruxolitinib.
8. Patients who have participated in other interventional (treatment-related) clinical trials within 30 days of enrollment are excluded.

**Baseline Assessment (within 4 weeks of starting treatment)**
1. Medical history including:
   a. disease characteristics such as first diagnosis of CMML, WHO/FAB subtype, IPSS score, MD Anderson Scoring System (MDASC), prior treatments.
   b. ECOG performance status.
   c. The Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF) at baseline and at best response.
   d. Concurrent medication review.
2. Routine physical examination to include vital signs, height and weight.
3. Bone marrow examination, including cytomorphology, cytogenetic assessment,
and flow cytometry analysis.

4. Laboratory assessments:
   • Hematology to include platelet count, hemoglobin, hematocrit, white blood cells (WBC) and WBC differential (including: neutrophils, eosinophils, basophils, lymphocytes and monocytes), INR, PT, PTT, and reticulocyte count.
   • Clinical chemistries including BUN/urea, creatinine, sodium, potassium, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, total bilirubin, albumin.
   • Urine or serum pregnancy test for females of childbearing potential will be performed at Screening or on Day 1, prior to first dose of study medication.

5. Review and record any blood and blood supportive care products for the prior 8 weeks.

<table>
<thead>
<tr>
<th>Treatment plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment will be administered on an outpatient basis. Reported adverse events and potential risks are described in Section 11. Appropriate dose modifications for ruxolitinib are described in Section 10. No investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's CMML. Ruxolitinib will be supplied by INCYTE as 5mg tablets containing ruxolitinib.</td>
</tr>
</tbody>
</table>

Ruxolitinib will be self-administered as a twice-daily oral dose for a continuous treatment cycle. Ruxolitinib tablets will be taken approximately 12 hours apart (morning and night). Subjects will not take the morning dose of ruxolitinib at the first regularly scheduled visit. Drug will be administered in the clinic in order to obtain adequate biomarker assessment. On all other days corresponding to study visits, subjects will take the morning dose of study drug prior to the visit, and will note on the subject reminder card the time that medications were taken.

Subjects will also be instructed to take ruxolitinib without respect to food, as previous data demonstrate no change in drug kinetics or absorption. The first patient will be given 10 mg/day divided in equal BID doses. Dose escalation guidelines are detailed below in section 10. In phase II of the study, a maximum of 29 subjects will be treated at the MTD identified in phase I. See study calendar for assessment on study.

<table>
<thead>
<tr>
<th>Dose delay/modifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>All subjects enrolled in phase 1 will start treatment on the assigned dose per cohort based on the dose escalation algorithm provided. Dose delays/modifications will not be allowed in phase 1 as it will interfere with the primary endpoint of this study. Dose delays/modifications are allowed for those subjects enrolled in phase II as described in section 6.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Definition of Dose-Limiting Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose-limiting toxicity (DLT) is defined as any grade 4 hematologic toxicity and any grade 3 or greater non-hematologic toxicity except nausea that is controlled by antiemetic therapy based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Grade 3 metabolic/electrolyte abnormalities that are not clinically significant, and are adequately controlled within 72 hours are not to be considered a DLT. To discern disease specific versus drug specific myelosuppression, Grade 4 thrombocytopenia will be defined as a decrease of ≥ 50% of baseline and a level of &lt; 25,000/uL. Grade 4 neutropenia will be defined as a decrease of ≥ 50% of baseline and a level of &lt;500/uL. Subjects will be evaluated for DLTs during the first and second cycles of therapy, i.e. 8 weeks for purpose of deciding the dose for next cohort (see dose escalation schema) but DLTs will continue to be evaluated and reported through all cycles on study.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Duration of Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects will be treated for a total of 16 weeks. For subjects responding at week 16, treatment may continue until one of the following criteria applies:</td>
</tr>
<tr>
<td>• Dose-limiting toxicity is reached,</td>
</tr>
<tr>
<td>• Inter-current illness that prevents further administration of treatment,</td>
</tr>
<tr>
<td>• Unacceptable adverse event(s),</td>
</tr>
<tr>
<td>• Patient decides to withdraw from the study, or</td>
</tr>
<tr>
<td>• General or specific changes in the patient’s condition render the patient unacceptable for further treatment in the judgment of the investigator.</td>
</tr>
<tr>
<td>• Evidence of disease progression by the IWG 2006 criteria.</td>
</tr>
</tbody>
</table>

Subjects who wish not to continue treatment will complete their end of study visit at week 16.
Subjects who were not enrolled in the MTD cohort can increase to the MTD after week 16 if the participant still meets the eligibility criteria. **Responding patients will be able to continue treatment until marketing approval of ruxolitinib for CMML.**

<table>
<thead>
<tr>
<th>Duration of Follow-Up</th>
<th>Subjects will be followed as per calendar on treatment for 17 weeks. After 17 weeks, subjects who continue on study will be followed monthly. Off study data on AML transformation and overall survival will be updated every 6 months or until death, whichever occurs first. Subjects removed from the study for unacceptable adverse events will be followed until resolution or stabilization of the adverse event.</th>
</tr>
</thead>
</table>

**Criteria for Removal from Study**
Study drug treatment can continue for subjects receiving clinical benefit, unless: one or more withdrawal criteria are met, or at the subject’s discretion, or if the study is terminated, or until the marketing approval for CMML.

*Subject Completion*
A subject will be considered to have completed the study if the subject meets at least 1 of the following criteria:
- The subject has completed 16 weeks of treatment with study medication with no improvement.
- The subject died during the study.
- The subject withdrew from study including subjects who experience a DLT.
- The subject experienced an AE that lead to withdrawal from the study.

*Subject Withdrawal from Study*
A subject may voluntarily withdraw from study medication or withdraw consent from the study at any time. The investigator may also, at his or her discretion, discontinue a subject from participating in the study at any time. The investigator will record the date and the reason for subject withdrawal from the study.

*Subject Withdrawal from Study Medication*
If the subject is permanently withdrawn from treatment with study medication, but does not withdraw consent, the investigator must make every effort to have the subject complete all withdrawal assessments at the time of withdrawal, and complete all scheduled follow-up visits.

**Treatment with study medication must be discontinued if (Withdrawal Criteria):**
- No clinical benefit has been attained after 16 weeks of treatment.
- Evidence of Disease progression according to IWG 2006 criteria.
- A subject experiences a DLT.
- A subject becomes pregnant.
- A subject is significantly non-compliant with the requirements of the protocol;
- A subject has an adverse experience that would, in the investigator’s judgment, make continued participation in the study an unacceptable risk.

<table>
<thead>
<tr>
<th>Follow up on study</th>
<th>See calendar page 36</th>
</tr>
</thead>
</table>

**Statistics**

**Study Design:**
This study will use a dose escalation, “rolling 6”design in Phase 1. Subjects will be allocated to starting doses of 10 mg/d to 40mg/d (divided in two equal doses) escalated by 10 mg/day for each cohort according to the predetermined algorithm outlined below in Table 1 (section 6.4). Each cohort will include 6 subjects. After testing the treatment dose on 10 patients in the first stage, the trial will be terminated if 1 or fewer desired respond. If the trial goes on to the second stage, a total of 29 patients will be studied. If the total number responding is less than or equal to 5, the drug is rejected.

*Sample Size/Accrual Rate*
If dose escalation is completed as planned a maximum of 53 (24 phase 1 and 29 in phase 2) are expected to enroll at a rate of 3 subjects every 1 month for stage I. The first phase of the stage II will recruit 10 subjects at the MTD. If 1 response are seen by 17 weeks on Ruxolitinib, then a total of 29 subjects will be accrued at the MTD to determine efficacy. Maximum accrual is 53 subjects.

**Analysis of the following secondary endpoints will be of exploratory nature:**

1. Acute myeloid leukemia (AML) transformation according to WHO criteria.
2. Overall survival (OS).
3. Duration of response.
4. The Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF) at baseline and at best response.
5. >50% decrease in splenic length as measured by physical exam
6. The suppression of pSTAT5 intracellular signaling after ruxolitinib in CMML subjects (pretreatment, at 1-2hr post treatment, cycle 2, cycle 4, and progression.)
7. Determine number of colonies formed in the presence of GM-CSF and/or ruxolitinib (pretreatment and progression) as a future predictor of response.
8. Mutational status in our CMML subjects by sanger sequencing of JAK2V617F, c-CBL, N-RAS, K-RAS, RUNX-1, TET2, SRSF2, EZH2, ASXL1, and DNMT3a (pretreatment and progression).
9. Mutational status of JAK2 tyrosine kinase at time of progression by deep sequencing of JAK2 to include M929I, Y931C, G935R, R938L, I960V, E985K. (pretreatment and at progression)

**Laboratory Correlates**

**Phases 1 and 2**
The pharmacokinetics of ruxolitinib has been extensively studied in subjects with myeloid malignancies. Ruxolitinib is quickly absorbed with peak levels at 1 to 3 hours after ingestion of the tablet. Because of this, subjects will take their first dose of ruxolitinib in the clinic. At that time, and three hours after taking the tablet, peripheral blood will be collected and processed in the lab of P.K. Epling-Burnette in the Stabile Research Building (SRB) at the Moffitt Cancer and Research Institute as described in section 16.

Using processed peripheral blood, pSTAT5 will be measured by flow cytometry at the time of tablet ingestion and 3 hours later. Bone marrow aspirates will also be used to perform colony formation assay as described in section 16 and to collect a minimum of 100 ug of DNA to interrogate the mutational status of the cohort studied as described in section 16.

---

**1 OBJECTIVES**
1.1 Primary Objective:
1.1.1 To evaluate the safety and tolerability of ruxolitinib in CMML subjects at diagnosis or relapse.
1.1.2 To determine overall response rates as measured by the international working group criteria (2006).
1.2 Secondary Objectives:
1.2.1 To determine the time to AML transformation of subjects on Ruxolitinib.
1.2.2 To determine the median overall survival.
1.2.3 To determine the duration of response achieved as in secondary endpoint one.
1.2.4 To determine the change in symptom score from baseline to best response.
1.2.5 To determine the change in spleen length at 16 weeks
1.2.6 To determine the change in downstream targets of JAK2 on ruxolitinib.
1.2.7 To determine if the *in vitro* activity of ruxolitinib correlates to response rates.
1.2.8 To determine if a correlation exist between the presence of the known recurrent mutations (JAK2, c-CBL, N-RAS, K-RAS, RUNX-1, TET2, SRSF2, EZH2, ASXL1, and DNMT3a) and response to ruxolitinib.
1.2.9 To determine non-V617F JAK2 mutations at end of study or progression and their clinical relevance in the context of ruxolitinib.

We recognize that this is a small study and the secondary objectives are of exploratory nature.

2 BACKGROUND

2.1 Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia (CMML) is a clonal malignancy characterized by cytopenias with or without leukocytosis, marrow dysplasia, monocytosis, splenomegaly, and a propensity to transform to acute myeloid leukemia. Prior to 2001, the World Health Organization (WHO) classified CMML as a subtype of the myelodysplastic syndromes (MDS). However because CMML exhibits clinical and pathologic features of a MDS and of a Myeloproliferative Neoplasm (MPN), it was reclassified by the WHO as a member of the Myelodysplastic/Myeloproliferative
Neoplasms (MDS/MPN) highlighting its nosologic complexity. CMML shares this WHO designation with atypical Chronic Myeloid Leukemia (aCML), Refractory Anemia with Ringed Sideroblasts and Thrombocytosis (RARS-T), and the pediatric counterpart of CMML, Juvenile Myelomonocytic Leukemia (JMML)\(^3\). JMML is a lethal pediatric malignancy with clinical features similar to CMML and hallmarked by selective hypersensitivity to GM-CSF\(^4\). The reclassification of CMML has been substantiated by next generation sequencing techniques that have allowed for the massive genetic sequencing of myeloid malignancies\(^5,6\). The occurrence of recurrent mutations in CMML and MDS are now known to be different in both type and/or frequency suggesting that these diseases represent distinctly different entities. The clinical behavior of CMML is unique in that it displays features of an MDS and of an MPN within the same patient. However, CMML subjects can display the predominant features of an MDS-like or MPN-like disease. The French-American-British (FAB) group was first to subdivide CMML subjects into an MDS variant and MPN variant based on a white blood cell (WBC) count greater than 20K/dL\(^7\). The WHO later favored subdivisions based on a myeloblast percentage greater than 10% in the bone marrow aspirate because of its prognostic value\(^3\). Irrespective of these subdivisions, recent genomic advances have yet to translate to effective, CMML specific therapies and thus the current standard-of-care in CMML remains the use of drugs developed for MDS.

For instance, in 2009, Fenaux and colleges reported the results of a randomized phase III trial that demonstrated a survival advantage (24.5mo vs 15mo) for 5-azacitidine, a DNA methyltransferase (DNMT) inhibitor, when compared with induction chemotherapy, low dose cytarabine, or best supportive care in subjects with higher risk MDS and CMML. However, only 22 CMMLs were included in this study and unequal randomization did not allow for subset analysis of these subjects\(^8\). Despite this, 5-azacitidine gained FDA approval for the treatment of CMML and has become the first line therapy of choice. Subsequent retrospective reports have suggested that the rates of hematologic improvement in CMML are similar to MDS but that this similarity is lost when analyzing the myeloproliferative variant of CMML alone. The
myeloproliferative variant appears to have response rates on the order of 10-15%\textsuperscript{9}.

Chronic Myelomonocytic Leukemia (CMML) is a rare disease with an incidence of approximately 0.3 per 100,000. The prognosis is poor with a median overall survival ranging between 12 and 20 months that is not known to be improved by 5-azacitidine\textsuperscript{10}. Allogeneic stem cell transplant (ASCT) remains the only potential curative therapy. However, most subjects are ineligible secondary to age related exclusion. Those that can undergo transplant face a high degree of morbidity and unacceptable transplant related mortality with only a small fraction of subjects alive at 5 years\textsuperscript{11}. From an economic perspective, an ASCT is costly as are the prophylactic antibiotics necessary to prevent life threatening infection and the immuno-suppressants needed to control graft versus host disease as a result of the transplant. To make matters worse, there are very few clinical trials available in CMML relative to other hematologic malignancies. This, in combination with its dismal prognosis and lack of standard therapies makes the outlook of subjects with CMML quite grim. There is a clear need for new CMML-specific therapies in this orphaned disease.

2.2 GM-CSF signaling and Chronic Myelomonocytic Leukemia

GM-CSF hypersensitivity, as defined by increased hematopoietic colony formation in methylcellulose when exposed to low dose GM-CSF, has been a known feature of JMML for over a decade\textsuperscript{4}. The obvious clinical similarities between JMML and CMML have lead to studies, including our own, investigating the nature of GM-CSF signaling in CMML. The first such study in 2002, Ramshaw and colleges showed that spontaneous hematopoietic colony growth could be achieved in CMML patient samples and that this was inhibited by E21R, a GM-CSF specific antagonist, suggesting that autocrine or paracrine production of GM-CSF was important to \textit{in vitro} CMML cell proliferation and differentiation. They also performed transplantation experiments in a NOD/SCID murine model that was transgenically modified to secrete human GM-CSF or not. Only those CMML cells transplanted in the GM-CSF transgenic mouse engrafted demonstrating an \textit{in vivo} requirement for proliferation\textsuperscript{12}. In the next study, Kotecha and colleges explored the downstream
signals elicited by the GM-CSF receptor in JMML. Despite the fact that JMML is predominantly a RAS-mediated disease, Kotecha and colleagues demonstrated that it was STAT5 and not ERK that was hyperphosphorylated in the presence of GM-CSF. This phenomenon was not seen in normal controls or other pediatric MPNs but was seen in five CMML patient samples.

Our laboratory has confirmed these results by demonstrating that CMML primary samples are sensitive to very low doses of GM-CSF as measured by STAT5 phosphorylation \(n=20\)\(^{14}\). We have also shown that GM-CSF inhibition is important to CMML viability by introducing KB-003, a highly specific monoclonal antibody to GM-CSF developed by KaloBios Pharmaceuticals. Despite the molecular and clinical heterogeneity observed in CMML, all samples tested \(n=10\) showed decrease proliferation and viability when exposed to GM-CSF blockade and the vast majority of samples tested \(n=20\) showed GM-CSF dependent STAT5 activation \(\text{Yp}\) at lower doses of GM-CSF compared to controls and compared to other cytokines within the CMML subjects. Further it was the immature monocytes \(\text{CD33^+}/\text{CD14^+}\) that seemed most sensitive to this inhibition, leaving the rest of the bone marrow unaffected.

2.3 Ruxolitinib

Ruxolitinib is an FDA-approved agent for the treatment of myelofibrosis. It is a potent inhibitor of JAK1 and JAK2 \(\text{nM IC50}\) that has been tested in a wide array of JAK/STAT dependent processes. In JAK/STAT dependent cell lines, ruxolitinib demonstrates IC50 values of 80-300 nM and can inhibit JAK/STAT signaling and growth in cell lines expressing the constitutively active JAK2 mutant \(\text{JAK2V617F}\) that is present in approximately 15% of CMML subjects\(^5\). The JAK2V617F abnormality has been broadly implicated in the pathogenesis of the majority of Philadelphia chromosome negative MPNs. It is because of this that INCYTE, the makers of ruxolitinib, have targeted MPNs in its initial drug development. To this end, \textit{in vivo} studies have demonstrated that Ruxolitinib improves splenomegaly and survival in a murine JAK/STAT dependent MPN model after only 3 weeks of
treatment. Treatment with ruxolitinib also reduced inflammatory cytokines and pSTAT3 levels in these mice suggesting an \textit{in vitro} and \textit{in vivo} effect in JAK/STAT dependent malignancies\textsuperscript{15}.

\textbf{Safety}

During the Phase I and Phase II development program, ruxolitinib was assessed in healthy volunteers, subjects with various degrees of renal or hepatic impairment, in subjects with rheumatoid arthritis, prostate cancer, multiple myeloma, myelofibrosis (MF), ploycythemia vera and essential thrombocythemia. The aggregate safety database for ruxolitinib included 679 subjects treated in 6 studies. Hematologic events were the most frequently reported adverse events (AE)s however, the majority of these were of Grades 1-2, seldom leading to study drug discontinuation (<1\% of subjects). Increased rates of anemia did result in an increase in packed red blood cell (PRBC) transfusion requirements for some ruxolitinib-treated patients but platelet transfusions while on ruxolitinib were rare. No Grade 4 events as it relates to biochemistry laboratory abnormalities of alanine aminotransferase (ALT), aspartate aminotransferase (AST) or cholesterol were reported. The Phase III safety dataset in MF patients shows that it was appropriate to individually adjust doses for patients according to their tolerability and efficacy. However, 124 patients (41.2\%) required no dose reduction, indicating the starting dose of 15mg or 20mg BID was appropriate for these individuals. Of the 177 patients who had dose reduction, 91 patients (51\%) had only one. Interruptions of dosing were less frequent than dose reductions, with 215 patients (71.4\%) requiring no dose interruption. Of the 86 patients who had dose interruptions, 59 patients (19.6\%) had only one dose interruption. The Phase III safety dataset in MF subjects showed that the only notable imbalances (ruxolitinib versus placebo or best available therapy [BAT]) in AEs related to hemorrhagic events were in Grade 1-2 skin and soft tissue bruising which did not lead to dose reduction or discontinuation. Similarly, the only notable imbalances (ruxolitinib versus placebo or BAT) in AEs related to infections were urinary tract infections and herpes zoster infections. A thorough QT study was conducted in 50 healthy subjects. There was no indication of a QT/QT\textsubscript{c} prolonging effect of ruxolitinib in single doses up that exceeded those proposed in this study\textsuperscript{16}. 
**Efficacy**

In two large phase 3 clinical trials, ruxolitinib has demonstrated efficacy in subjects with high-risk myelofibrosis. The first trial randomly assigned subjects to receive 15mg twice daily of ruxolitinib (155 subjects) or placebo (154 subjects). The primary endpoint of the study was defined as the proportion of subjects with a reduction in spleen volume of 35% or more at 24 weeks by means of magnetic resonance imaging (MRI). The primary end point was reached in 41.9% of subjects in the ruxolitinib group as compared with 0.7% in the placebo group (P<0.001). A reduction in spleen volume was durable as 67.0% of the subjects with a response had the response for 48 weeks or more. There was an improvement of 50% or more in the total symptom score, a myelofibrosis specific quality-of-life scoring system, at 24 weeks in 45.9% of subjects who received ruxolitinib as compared with 5.3% of subjects who received placebo (P<0.001)\(^{17}\). The second trial randomly assigned subjects to the same dose of ruxolitinib or best available therapy (BAT) defined by the treating physician. The primary end point was the percentage of subjects with at least a 35% reduction in spleen volume at week 48 by MRI or computed tomography. A total of 28% of the subjects in the ruxolitinib group met the primary endpoint as compared with 0% in the group receiving the best available therapy (P<0.001). At 48 weeks, the mean palpable spleen length had decreased by 56% with ruxolitinib but had increased by 4% with the best available therapy. The median duration of response with ruxolitinib was not reached, with 80% of subjects still having a response at a median follow-up of 12 months\(^{18}\).

2.4 **Rationale for Ruxolitinib in CMML**

GM-CSF signaling is both dysregulated and important for CMML survival *in vitro* and *in vivo* (see section 2.2). Although GM-CSF signaling is hallmarkmed by cytokine pleotropy, it appears that STAT5 is preferentially activated in the CMML disease phenotype. Our laboratory has shown that targeting GM-CSF activation leads to decreased viability in primary CMML patient samples. In the late 1990s, efforts were made to target this pathway. Frankel and colleagues developed a GM-CSF molecule fused to diphtheria toxin that was highly toxic to CMML myeloid progenitors in
16/20 patient samples tested. This led to a phase I clinical trial in relapsed/refractory acute leukemias. Unfortunately, unacceptable hepatotoxicity was seen, even at moderate doses of compound, that did not allow for dose escalation. This hepatotoxicity is now thought to be Kupffer cell mediated.

The JAK kinases are the sentinel kinases responsible for the key phosphorylation event in many cytokine receptors, including GM-CSF. Parganas and colleges developed a JAK2 deficient murine model that showed that JAK2 is required to elicit GM-CSF mediated signaling. Considering this, our laboratory explored JAK1/2 pharmacologic inhibition with SD1029 in primary CMML cells. SD-1029 is a selective JAK1/JAK2 (µM IC50) inhibitor that is not available for clinical use and has a similar JAK inhibition profile to ruxolitinib. In 3 CMML patient samples tested, SD-1029 increased apoptosis and decreased viability by ANNEXIN-V and DAPI staining in a dose dependent fashion. None of these subjects tested harbored a JAK2V617F mutation. Lastly, Ravandi and colleges recently published the results of a phase 2 trial using ruxolitinib in refractory leukemias. In this cohort, 4 CMML subjects were enrolled to take BID ruxolitinib (dose not available). It is reported that 2/4 CMML subjects demonstrated some degree of clinical benefit. Although the nature of the benefit was not expounded upon, it provides further proof-of-principle that JAK inhibition may indeed result in responses in this disease. Our preliminary data, in addition to the extensive data demonstrating the role of GM-CSF in CMML, provides compelling evidence to explore JAK1/2 inhibition with ruxolitinib as a therapeutic target in CMML.

3 STUDY ENDPOINTS
3.1 Primary
3.1.1 The maximum tolerated dose (MTD) of ruxolitinib for the treatment of CMML. The MTD is defined as the highest dose where less than 33% of subjects experience a drug related predefined dose limited toxicity (DLT).

3.1.2 Proportion of subject achieving clinical benefit defined as hematologic improvement, complete remission, partial remission, or stable disease by the IWG 2006 criteria (see appendix B)
3.2 Secondary
3.2.1 Acute myeloid leukemia (AML) transformation according to WHO criteria.
3.2.2 Overall survival (OS).
3.2.3 Duration of response.
3.2.4 The Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF) at baseline and at best response.
3.2.5 >50% decrease in splenic length as measured by physical exam if applicable
3.2.6 The suppression of pSTAT5 intracellular signaling after ruxolitinib in CMML subjects (pretreatment, at 1-2hr post treatment, cycle 2, cycle 4, and progression.)
3.2.7 Determine number of colonies formed in the presence of GM-CSF and/or ruxolitinib (pretreatment and progression) as a future predictor of response.
3.2.8 Mutational status in our CMML subjects by sanger sequencing of JAK2, c-CBL, N-RAS, K-RAS, RUNX-1, TET2, SRSF2, EZH2, ASXL1, and DNMT3a (pretreatment and progression).
3.2.9 Mutational status of JAK2 tyrosine kinase at time of progression by deep sequencing of JAK2 to include M929I, Y931C, G935R, R938L, I960V, E985K. (pretreatment and at progression)

4 PATIENT SELECTION
4.1 Eligibility criteria
4.1.1 Confirmed diagnosis of CMML using the World Health Organization (WHO) classification (appendix E).
4.1.2 Age >18 years at the time of obtaining informed consent.
4.1.3 Must be able to adhere to the study visit schedule and other protocol requirements.
4.1.4 Subjects must be able to provide adequate BM aspirate and biopsy specimens for histopathological analysis and standard cytogenetic analysis during the screening procedure.
4.1.5 An Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 is required.
4.1.6 Women of childbearing potential must have a negative pregnancy test at time of screening and baseline visits and agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse
1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device [IUD], hormonal [birth control pills, injections, or implants], tubal ligation, partner’s vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap).

4.1.7 Must understand and voluntarily sign an informed consent form.

4.1.8 Must have a life expectancy of greater than 3 months at time of screening.

4.2 Exclusion Criteria

4.2.1 Any of the following lab abnormalities:

4.2.1.1 Platelet count of less than 35,000/μL

4.2.1.2 Absolute Neutrophil Count (ANC) of less than 250 cells/μL

4.2.1.3 Serum Creatinine ≥ 2.0

4.2.1.4 Serum total bilirubin > 1.5 x ULN

4.2.2 Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of CMML within 28 days of the first day of study drug treatment.

4.2.3 Any serious medical condition or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he/she participates in the study.

4.2.4 Concurrent use of GM-CSF. G-CSF could be used for the short-term management of neutropenic infection. Stable doses of erythropoietin stimulating agents that were started > 8 weeks from first ruxolitinib dose or corticosteroids that were being administered prior to screening are allowed.

4.2.5 Uncontrolled current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

4.2.6 History of metastatic malignancy in the preceding 2 years.

4.2.7 Pregnant women are excluded from this study because ruxolitinib has not been studied in pregnant subjects. Because there is an unknown but potential risk for
adverse events in nursing infants secondary to treatment of the mother with ruxolitinib, breastfeeding should be discontinued if the mother is treated with ruxolitinib.

4.2.8 Patients who have participated in other interventional (treatment-related) clinical trials within 30 days of enrollment are excluded.

4.3 Inclusion of Women and Minorities
Both men and women and members of all races and ethnic groups are eligible for this trial.

5 STUDY DESIGN
This is a phase 1/2, two-stage, sequential cohort dose escalation study. In phase 1, subjects will be allocated to BID doses of 10 mg/d up to 40 mg/d. The starting dose will be 10 mg/d (5 mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional subjects will be treated during the first stage of phase 2 (stage 1) at the MTD. The trial will be terminated if 1 or fewer respond. If the trial goes on to the second stage, a total of 29 patients will be studied to determine efficacy in phase 2.

6 TREATMENT PLAN
6.1 Ruxolitinib administration
Subjects will not take the morning dose of ruxolitinib at the first regularly scheduled visit. Drug will be administered in the clinic in order to obtain adequate biomarker assessment. On all other days corresponding to study visits, subjects will take the morning dose of study drug prior to the visit, and will note on the subject reminder card the time that medications were taken. Reported adverse events and potential risks are described in Section 11. Appropriate dose modifications for ruxolitinib are described in Section 10. No investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's CMML.

6.1.1 Ruxolitinib will be supplied by INCYTE as tablets that will be self-administered BID orally, with or without food approximately 12 hours apart (morning and night).
6.1.2 The dosage strength is 5 mg/tablet Ruxolitinib phosphate (free base equivalent). Administration instructions will be provided at Study Visits. The administration instructions will state that medication is “For Investigational Use Only”. Ruxolitinib 5 mg tablets are packaged as 60 count in high-density polyethylene (HDPE) bottles. The bottles will include labeling “New Drug - Limited by Federal (USA) Law to Investigational Use. The bottles of tablets should be stored at room temperature, 15°C to 30°C (59°F to 86°F). Dose escalation guidelines are detailed below in section 6.5. In phase II of the study, a maximum of 29 subjects will be treated at the MTD identified in phase I.

6.2 Definition of Dose-Limiting Toxicity
Dose-limiting toxicity (DLT) is defined as any grade 4 hematologic toxicity and any grade 3 or greater non-hematologic toxicity except nausea that is controlled by antiemetic therapy based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Criteria for Grade 3 renal toxicity are consistent with prescribing information with respect to renal impairment and safe use of ruxolitinib. Grade 3 metabolic/electrolyte abnormalities that are not clinically significant, and are adequately controlled within 72 hours are not to be considered a DLT. To discern disease specific versus drug specific myelosuppression, Grade 4 thrombocytopenia will be defined as a decrease of ≥ 50% of baseline and a level of < 25,000/uL. Grade 4 neutropenia will be defined as a decrease of ≥ 50% of baseline and a level of <500/uL. Previous clinical trials testing ruxolitinib reported a hematologic nadir of 8 weeks. As such, DLTs during the first and second cycle of therapy, i.e. 8 weeks, will be used for the purpose of deciding the dose for next cohort (see dose escalation schema) but DLTs will continue to be evaluated and reported through all cycles on study. Management and dose modifications associated with the above adverse events are outlined in Section 11.

6.2.1 Dose escalation will proceed according to the following scheme:

<table>
<thead>
<tr>
<th>Dose Escalation Schedule</th>
</tr>
</thead>
</table>

18
<table>
<thead>
<tr>
<th>Dose Level</th>
<th>Dose of Ruxolitinib (per day given in equal BID doses)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 1</td>
<td>10 mg</td>
</tr>
<tr>
<td>Level 2</td>
<td>20 mg</td>
</tr>
<tr>
<td>Level 3</td>
<td>30 mg</td>
</tr>
<tr>
<td>Level 4</td>
<td>40 mg</td>
</tr>
</tbody>
</table>

6.3 Definition of Maximum Tolerated Dose

The maximum tolerated dose (MTD) is defined as the highest dose where < 33% of subjects experience DLT.

Dose Escalation Scheme

In phase 1 of this study, subjects will be allocated to starting doses (10 mg/d to be escalated up to 40mg/d, which is outlined in the table above). The second phase of the study (phase 2) will enroll a maximum of 29 subjects at the MTD determined in phase 1. In each cohort in the phase I study, up to 6 subjects will be enrolled. Based on whether DLTs are observed during 8 weeks of treatment, the dose for the subsequent cohort will be determined. If no DLT is observed during an 8 week period then another 6 subjects will be enrolled at the next dose level (see section 6.2.1 table). If 1 DLT is observed after three subjects are enrolled then dose escalation will continue at the same dose level until 6 total patients are enrolled. If a total 1 of 6 subjects enrolled experience at DLT after all subjects have had an 8 week monitoring period then dose escalation can proceed. If 2 or more of 6 total subjects experience a DLT then dose escalation is complete and the MTD will be the antecedent dose level. Dose escalation will proceed according to the following scheme. Dose-limiting toxicity (DLT) is defined above.

6.3.1 Dose Escalation Rules of Rolling Six Design

<table>
<thead>
<tr>
<th>Cohort</th>
<th>DLT Data</th>
<th>Enrolling Dose level</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. Enrolled</td>
<td>No. DLTs</td>
<td>No. without DLT</td>
</tr>
<tr>
<td>2</td>
<td>0,1</td>
<td>Any</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>0,1,2</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>0,1</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>&gt;1</td>
<td>Any</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>0,1,2</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>0,1</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>&gt;1</td>
<td>Any</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>0,1,2</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>3,4</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>0,1</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>3,4</td>
</tr>
<tr>
<td>5</td>
<td>&gt;1</td>
<td>Any</td>
</tr>
<tr>
<td>6</td>
<td>0</td>
<td>0,1,2</td>
</tr>
<tr>
<td>6</td>
<td>0</td>
<td>3,4</td>
</tr>
<tr>
<td>6</td>
<td>0</td>
<td>5,6</td>
</tr>
<tr>
<td>6</td>
<td>1</td>
<td>0,1</td>
</tr>
<tr>
<td>6</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>1</td>
<td>3,4</td>
</tr>
<tr>
<td>6</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>6</td>
<td>&gt;1</td>
<td>Any</td>
</tr>
</tbody>
</table>

Adapted from Skolnik, et al. Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design. JCO 2008 n=current dose level. n+1=dose escalation. n-1=dose de-escalation. Pending data=less than 8 weeks of follow-up data.

6.4 **General Concomitant Medication and Supportive Care Guidelines**

All concomitant medications and medication history for 2 weeks MUST be recorded in the eCRF, and include: drug name, dose, frequency of administration, start and stop dates, and indication. All prior medications used to treat CMML will be recorded regardless of when they were received by the subject. Information collected for these medications will include dates of use, best treatment response (eg, disease improvement, stabilization of disease or no improvement/disease progression), and reasons for stopping therapy. Any change in dosage of any concomitant medication (change in dose or frequency) MUST be recorded in the eCRF, to include: drug name, dose, frequency of administration, start and stop dates and indication.
6.5  **Permitted Medications**

6.5.1.1  **Growth Factors**

Erythropoiesis-stimulating agents (ESAs) are allowed for anemia during the study as per accepted standards in the treatment of CMML as long as the ESA was initiated >8 weeks prior to the first dose of ruxolitinib. Subjects who enter the study on ESAs should continue at the same dose schedule until the optimal dose of study medication has been established. G-CSF is allowed during the study for subjects with severe neutropenia and recurrent infections. Subjects who enter the study on G-CSF should continue at the same dose schedule until the optimal dose of study medication has been established. GM-CSF is not permitted at any time during the study as preclinical evidence suggests that GM-CSF may be important for CMML proliferation and survival.

6.5.1.2  **Systemic corticosteroids**

Systemic corticosteroid doses greater than the equivalent of 10 mg prednisolone per day is not permitted, unless use is part of an ruxolitinib-dose tapering strategy. (see section 7 Optional Dose Tapering Strategy).

6.5.1.3  **Aspirin**

Aspirin in doses exceeding 162 mg per day is not permitted. Low dose aspirin (≤ 162 mg/day) and non steroidal anti-inflammatory agents (acetaminophen, Ibuprofen) may be used.

6.5.1.4  **Medications that are inhibitors of CYP3A4**

When concomitant administration of a potent systemic inhibitor of CYP3A4 metabolizing enzymes (ketoconazole, clarithromycin, itraconazole, nefazodone and telithromycin, see section 7) that is required for subject management, the dose of ruxolitinib tablets must be adjusted as described in section 7. Based on the low overall bioavailability of topical ketoconazole, with very low systemic levels seen following topical administration, no dose adjustment of ruxolitinib is needed for use with topical ketoconazole.

6.5.1.5  **Blood Products**

The use of blood products to include packed red blood cells (PRBCs) and platelet transfusions are permitted and to be given at the discretion of the
treating physician. Recommended guidelines for transfusion include a platelet threshold of 10,000/L for platelet transfusion and a hemoglobin threshold of 8g/dL for PRBC transfusion.

6.6 Prohibited Medications
Subjects must abstain from using prohibited prescription or non-prescription drugs within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication and until completion of follow-up procedures (Exclusion Criteria). The following medications are prohibited during the study:

- Any prior or concomitant use of another JAK inhibitor.
- Any investigational medication other than the study drugs.
- Use of the potent inducers of CYP3A4, rifampin and St John’s Wart, is not permitted at any time during participation in the study.
- The GM-CSF growth factor receptor agonists must not be used. Preclinical evidence suggest that it is important for CMML proliferation and survival and it is directly upstream for JAK2, the target of ruxolitinib. GM-CSF must not have been used for at least 28 days prior to receiving the first dose of study drug.

7 Duration of Therapy
Subjects will be treated for a total of 16 weeks. For subjects responding at week 16, treatment may continue until one of the following criteria applies:

7.1 Dose-limiting toxicity is reached,
7.2 Inter-current illness that prevents further administration of treatment,
7.3 Unacceptable adverse event(s),
7.4 Patient decides to withdraw from the study, or
7.5 General or specific changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator.

7.6 Evidence of disease progression by the IWG 2006 criteria.
Subjects who wish not to continue treatment will complete their end of study visit at week 17. Subjects who were not enrolled in the MTD cohort can increase to the MTD after week 17 if the participant still meets the eligibility criteria. Responding patients will be able to continue until marketing approval of ruxolitinib for CMML.
8 Duration of Follow-Up

Subjects will be followed as per calendar on treatment for 17 weeks. After 17 weeks patient who continue on study will be followed monthly. Off study data on AML transformation and overall survival will be updated every 6 month or until death, whichever occurs first. Subjects removed from study for unacceptable adverse events will be followed until resolution or stabilization of the adverse event.

9 Criteria for Removal from Study

9.1 Subject Completion

A subject will be considered to have completed the study if the subject meets at least 1 of the following criteria:

9.1.1 The subject has completed 16 weeks of treatment with study medication with no improvement.

9.1.2 The subject died during the study.

9.1.3 The subject withdrew from study including subjects who experience a DLT.

9.1.4 The subject experienced an AE that lead to withdrawal from the study.

9.2 Subject Withdrawal from Study

9.2.1 A subject may voluntarily withdraw from study medication or withdraw consent from the study at any time. The investigator may also, at his or her discretion, discontinue a subject from participating in the study at any time. The investigator will record the date and the reason for subject withdrawal from the study.

9.3 Subject Withdrawal from Study Medication

If the subject is permanently withdrawn from treatment with study medication, but does not withdraw consent, the investigator must make every effort to have the subject complete all withdrawal assessments at the time of withdrawal, and complete all scheduled follow-up visits. Treatment with study medication must be discontinued if:

- The subject withdraws consent.
- Further participation would be injurious to the subject’s health or well-being in the Investigator’s medical judgment.
• The study is terminated.
• Marketing approval of CMML
• The subject becomes pregnant
• The subjects exhibits leukemic transformation (as evidenced by bone marrow blast counts of at least 20%, or peripheral blast counts of at least 20% lasting at least 8 weeks.
• No clinical benefit has been attained after 16 weeks of treatment.
• Evidence of Disease progression according to IWG 2006 criteria.
• a subject experiences a DLT.
• a subject is significantly non-compliant with the requirements of the protocol.
• a subject has an adverse experience that would, in the investigator’s judgment, make continued participation in the study an unacceptable risk.

10 DOSING DELAYS/MODIFICATIONS
All subjects enrolled in the phase 1 portion will start treatment on the assigned dose per cohort based on the dose escalation algorithm provided. No dose delays or modifications are allowed during this period. All subjects enrolled in the phase 2 portion may have the following dose delays/modifications once the MTD has been defined.

Ruxolitinib may be held by the Investigator at any time if there is concern about subject safety. Dosing must be halted immediately if either of the following occurs:
• Platelet counts fall below 10,000/μL and/or a life-threatening bleeding event
• Febrile neutropenia

Dosing may be reinstated following dose interruption using the re-start schema detailed in below.

10.1 Dose Adjustments.
In order to provide sufficient data to make the dose adjustment decisions, it is recommended that hematology parameters be obtained weekly and at least two times weekly for platelet count < 25,000/μL or ANC < 500/μL. In the event that any subject permanently discontinues the study drug, regardless of reason, reasonable efforts should be made to have the subject return for an early termination visit. If the drug discontinuation is being contemplated for a reason other than low platelet count or
low ANC, the use of a tapering strategy should be considered (see below). The date the subject discontinued the study drug and the specific reason for discontinuation will be recorded in the eCRF; e.g., reasons such as discontinued due to inadequate efficacy or withdrawn due to adverse event. This information will be used to summarize the reasons for study discontinuation. Efforts will be made to follow subjects who discontinue from the study in order to determine overall survival and leukemia free survival. Investigators will contact subjects every 6 months to determine if subjects have undergone leukemic transformation, or death, and for the latter, the cause of death.

10.2 Dose Adjustments in Ruxolitinib Tablets for Safety.

Dose adjustments apply to the phase 2 portion of this study. There are no dose adjustments allowed during phase 1. Dosing must be held if platelet counts decline below 10,000/μL or if a life-threatening bleed occurs with a platelet count below 20,000/μL. Doses must be decreased for platelet count values that decline greater than 50% of baseline and are greater than 25,000/μL to 75% of the defined MTD. Doses must be decreased for platelet count values that decline greater than 50% of baseline and are below 25,000/μL to 50% of the defined MTD. The dosing schedule should be maintained at BID dosing to assure appropriate pharmacokinetics. Dose reductions should be executed by decreasing the individual dose and not the frequency of administration. In order to provide sufficient data to make the dose adjustment decisions, it is recommended that hematology parameters be obtained as defined in section 10.1. Dosing may be restarted or increased following recovery of platelet counts to acceptable levels. The following is the recommended dose restart/increase strategy:

In subjects whom drug was held, ruxolitinib may be restarted at 50% of the MTD after platelet count has improved to pre-ruxolitinib baseline levels and/or febrile neutropenia has resolved for at least 2 weeks. In subjects whom drug dose was decreased, ruxolitinib may be increased to the previous dose (MTD) after platelet count has improved to pre-ruxolitinib baseline levels and/or febrile neutropenia has resolved for at least 2 weeks. If criteria is met for discontinuation/dose modification then ruxolitinib must be discontinued with no potential for restart. The objective for
restarting or escalating after a reduction for safety is to find the highest safe dose of ruxolitinib for each subject, with increases in dose generally not more than in increments of 5 mg BID and not more often than every 2 weeks. Subjects who were not enrolled in the MTD cohort can increase to the MTD after week 17 if the participant still meets the eligibility criteria. Non hematological toxicity dose adjustment criteria

10.3 Dose Reductions for Concomitant CYP Inhibitor Usage
Ruxolitinib is metabolized in the liver by the cytochrome (CYP) P450 metabolizing enzyme system, predominantly by the 3A4 isozyme. With concomitant dosing of potent CYP3A4 inhibitors such as systemic ketoconazole (see Appendix C), plasma exposure of Ruxolitinib increases approximately 2-fold. Thus, a dose reduction of ~50% for Ruxolitinib is appropriate for subjects who take systemic ketoconazole or other potent CYP3A4 inhibitors systemically as concomitant medication. BID doses will be decreased to the corresponding once daily dose as follows:

- If dose is 20 mg BID, change dose to 20 mg QD
- If dose is 15 mg BID, change dose to 15 mg QD
- If dose is 10 mg BID, change dose to 10 mg QD
- If dose is 5 mg BID, change dose to 5 mg QD
- If dose is 5 mg QD, no dose change is required.

Potent inhibitors of CYP3A4 include systemic ketoconazole, clarithromycin, itraconazole, nefazodone and telithromycin. NOTE: once the course of therapy using a CYP3A4 inhibitor has been completed, the subject should resume his/her prior BID dose regimen of study drug beginning the next day.

10.4 Dose Reductions for Hepatic Impairment
Hepatic impairment will be classified by the NCI Organ Dysfunction Working Group criteria. Any hepatic dysfunction classified as moderate or severe will require the treating physician to hold study drug until two week after hepatic dysfunction can be classified as mild or normal by NCI criteria. Ruxolitinib may be restarted at 50% of the MTD. If moderate or severe hepatic impairment occur a second time in the same subject, ruxolitinib will be discontinued.
ADVERSE EVENTS: REPORTING REQUIREMENTS

The investigator or site staff will be responsible for detecting, documenting and reporting events that meet the definition of an AE or SAE. All Adverse events will be reported to the principle investigator, Eric Padron and study coordinator at 813-745-5758.

11.1 Definition of an AE

Any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.

Events meeting the definition of an AE include:

• Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition.
• New conditions detected or diagnosed after investigational product administration even though it may have been present prior to the start of the study.
• Signs, symptoms, or the clinical sequelae of a suspected interaction
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either investigational product or a concomitant medication (overdose per se will not be reported as an AE/SAE). “Lack of efficacy” or “failure of expected pharmacological action” per se within the duration of initial ruxolitinib treatment/exposure of 16 weeks will not be reported as an AE or SAE. However, the signs and symptoms and/or clinical sequelae resulting from lack of efficacy will be reported if they fulfill the definition of an AE or SAE.

Events that do not meet the definition of an AE include:

• Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that leads to the procedure is an AE
• Situations where an untoward medical occurrence did not occur (social and/or convenience admission to a hospital)
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen
• The disease/disorder being studied or expected progression, signs, or symptoms of
the disease/disorder being studied, unless more severe than expected for the subject’s
condition.
• Death due to the disease being studied.

11.2 Definition of an SAE
A serious adverse event is any untoward medical occurrence that, at any dose:
• Results in death
• Is life-threatening
NOTE: The term “life-threatening” the definition refers to an event in which the
subject was at risk of death at the time of the event. It does not refer to an event,
which hypothetically might have caused death, if it were more severe.
• Requires hospitalization or prolongation of existing hospitalization.
NOTE: In general, hospitalization signifies that the subject has been detained (usually
involving at least an overnight stay) at the hospital or emergency ward for
observation and/or treatment that would not have been appropriate in the physician’s
office or out-patient setting. Complications that occur during hospitalization are AEs.
If a complication prolongs hospitalization or fulfills any other serious criteria, the
event is serious. When in doubt as to whether “hospitalization” occurred or was
necessary, the AE should be considered serious. Hospitalization for elective treatment
of a pre-existing condition that did not worsen from baseline is not considered an AE.
• Results in disability/incapacity
NOTE: The term disability means a substantial disruption of a person’s ability to
conduct normal life functions. This definition is not intended to include experiences
of relatively minor medical significance such as uncomplicated headache, nausea,
vomiting, diarrhea, influenza, and accidental trauma (e.g. sprained ankle) which may
interfere or prevent everyday life functions but do not constitute a substantial
disruption.
• Is a congenital anomaly/birth defect
• All treatment related grade 4 non-hematologic laboratory abnormalities assessed
using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse
Events (CTCAE) v 4.0.
Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

11.3 Relationship to Investigational Product

It is a regulatory requirement for investigators to assess relationship to investigational product based on information available. The assessment should be reviewed on receipt of any new information and amended if necessary. “A reasonable possibility” is meant to convey that there are facts/evidence or arguments to suggest a causal relationship. Facts/evidence or arguments that may support “a reasonable possibility” include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge. Confounding factors, such as concomitant medication, a concurrent illness, or relevant medical history, should also be considered.

11.4 Laboratory and Other Safety Assessment Abnormalities Reported as AEs and SAEs

Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (e.g., ECGs, radiological scans, vital signs measurements), including those that worsen from baseline should be recorded as per the NCI-CTC AE criteria. However, these laboratory results are to be recorded as AEs or SAEs if deemed clinically significant in the medical and scientific judgment of the investigator or treating physician. Any clinically significant safety assessments that are associated with the underlying disease are not to be reported as AEs or SAEs, except for findings judged by the investigator or treating physician to be more severe than expected for the subject’s condition or death. Data will be collected for typical disease-related events such as anemia, leukocytopenia or worsening of
thrombocytopenia. All infections experienced during the study are to be recorded as AEs or SAEs.

11.5 Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as SAEs

During the study period, the following conditions will not qualify as an AE or SAE provided they are not considered attributable to study medication:

- cases of disease progression.

11.6 Pregnancy

Any pregnancy that occurs during study participation must be reported. To ensure subject safety, each pregnancy must be reported to the FDA with CC notification to INCYTE IncytePhVOpsLST@incyte.com within 2 weeks of learning of its occurrence. The pregnancy must be followed up to determine outcome (including premature termination) and status of mother and child. Pregnancy complications and elective terminations for medical reasons must be reported as an AE or SAE. Spontaneous abortions must be reported as an SAE. Any SAE occurring in association with a pregnancy, brought to the investigator’s attention after the subject has completed the study and considered by the investigator as possibly related to the investigational product, must be promptly reported to the pharmacovigilance group at the H. Lee Moffitt Cancer Center. In addition, the investigator must attempt to collect pregnancy information on any female partners of male study subjects who become pregnant while the subject is enrolled in the study. Pregnancy information must be reported to the H. Lee Moffitt Cancer Center as described above.

11.7 Time Period and Frequency of Detecting AEs and SAEs

The investigator or site staff is responsible for detecting, documenting and reporting events that meet the definition of an AE or SAE. AEs will be collected from the start of Investigational Product and through the follow-up contact. SAEs will be collected over the same time period as stated above for AEs. However, any SAEs assessed as related to study participation (e.g., investigational product, protocol mandated procedures, invasive tests, or change in existing therapy) will be recorded from the time a subject consents to participate in the study up to and including any follow-up
contact. All SAEs will be reported to INCYTE IncytePhVOpsIST@incyte.com within 24 hours, as indicated.

11.8 Prompt Reporting of Serious Adverse Events and Other Events to the FDA with notification to INCYTE

Any serious adverse events which occur during the clinical study or within 30 days of receiving the last dose of study medication, whether or not related to the study drug, must be reported by the investigator. In addition, any SAEs which occur as a result of protocol specific diagnostic procedures or interventions must also be reported. SAEs brought to the attention of the investigator at any time after cessation of ruxolitinib and considered by the investigator to be related or possibly related to ruxolitinib must be reported to FDA with notification to INCYTE IncytePhVOpsIST@incyte.com if and when they occur. Additionally, in order to fulfill international reporting obligations, SAEs that are related to study participation (e.g., procedures, invasive tests, change from existing therapy) or are related to a concurrent medication will be collected and recorded from the time the subject consents to participate in the study until he/she is discharged.

<table>
<thead>
<tr>
<th>Type of Event</th>
<th>Initial Reports</th>
<th>Follow-up Information on a Previous Report</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Time Frame</td>
<td>Documents</td>
</tr>
<tr>
<td>All SAEs</td>
<td>24 hours*</td>
<td>“SAE” data collection tool</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>2 Weeks*</td>
<td>Pregnancy Notification Form</td>
</tr>
</tbody>
</table>

- From the time point when the SAE or pregnancy became known to reporter.

11.9 Regulatory Reporting Requirements for SAEs

Prompt notification of SAEs by the investigator to the FDA (and INCYTE IncytePhVOpsIST@incyte.com) is essential so that legal obligations and ethical responsibilities towards the safety of subjects are met. The sponsor-investigator has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a product under clinical investigation. The sponsor-investigator will comply with specific regulatory requirements relating to safety
reporting to the regulatory authority, Institutional Review Board (IRB), the FDA, notification to INCYTE, and sub-investigators. Investigator safety reports are prepared for suspected unexpected serious adverse reactions according to local regulatory requirements and those policies set forth by the FDA and are forwarded to investigators and INCYTE as necessary. An investigator who receives an investigator safety report describing an SAE(s) or other specific safety information (e.g., summary or listing of SAEs) from the H. Lee Moffitt Cancer Center will file it with the CIB and will notify the IEC /IRB, if appropriate according to local requirements.

12 PHARMACEUTICAL INFORMATION

12.1 Packaging and Labeling

Ruxolitinib 5 mg tablets are packaged as 60 count in high-density polyethylene (HDPE) bottles. The bottles will include labeling “New Drug - Limited by Federal (USA) Law to Investigational Use.

12.2 Preparation

Tablets will be provided to the site and no specific preparation of study medication is required prior to administration.

12.3 Handling and Storage

Investigational product must be dispensed or administered according to procedures described herein. Only subjects enrolled in the study may receive investigational product, in accordance with all applicable regulatory requirements. Only authorized site staff may supply or administer investigational product. All investigational products must be stored in a secure area with access limited to the investigator and authorized site staff and under physical conditions that are consistent with investigational product-specific requirements. The bottles of tablets should be stored at room temperature, 15°C to 30°C (59°F to 86°F). Any unused investigational product will be returned to INCYTE for destruction or destroyed at the institution per institutional policy (if allowable).

13 Study Calendar

All screening evaluations will be performed within 4 weeks prior to the start of ruxolitinib treatment. Subjects must have a bone marrow biopsy and aspirate (including
cytogenetics) performed within 4 weeks prior to the start of treatment. All transfusion and pre-transfusion Hgb or platelet count must be recorded for the 8 weeks prior to initiation of study treatment. Strict adherence to the visit schedule is required. In the event that a visit or test cannot be scheduled on the exact visit day, a window of ± 7 days is allowable. Bone marrow aspiration and biopsy exams can be done within a 14 day window of the allotted date. Tests (including bone marrow biopsies and aspirates) done within the screening period prior to signing informed consent are allowed for use in this study.

13.1 **Baseline Assessment:** within 4 weeks of starting treatment

Medical history including:
- disease characteristics such as first diagnosis of CMML, WHO/FAB subtype, IPSS score, MD Anderson Scoring System (MDASC), prior treatments.
- ECOG performance status.
- Concurrent medication review.
- red blood cell and platelets transfusion past 8 weeks if available.
- Routine physical examination to include vital signs, height and weight.
- Bone marrow examination, including cytomorphology, cytogenetic assessment, and flow cytometry analysis.
- Laboratory assessments:
  - Hematology to include platelet count, hemoglobin, hematocrit, white blood cells (WBC) and WBC differential (including: neutrophils, eosinophils, basophils, lymphocytes and monocytes), INR, PT, and PTT and reticulocyte count.
  - Clinical chemistries including BUN/urea, creatinine, sodium, potassium, alkaline phosphatase, alanine aminotransferase (ALT), aspartateaminotransferase (AST), total bilirubin, bicarbonate, calcium, chloride, glucose, LDH, total protein, albumin.
  - Urine or serum pregnancy test for females of childbearing potential will be performed at Screening or on Day 1, prior to first dose of study medication.

•Symptom Score using the The Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF). (see Appendix D)
Review and record any blood and blood supportive care products for the prior 8 weeks.

13.2 **Treatment Period** (weeks 1-16): Ruxolitinib will be administered as a twice daily oral dose for a 4-week treatment cycle. Subjects will have a CBC with leukocyte differential performed weekly; a blood chemistry will be performed weekly for first cycle and then q 2 weeks. A BM aspirate and biopsy with cytogenetic analysis will be performed after cycle 2 and 4 (weeks 8, 16) to assess pathologic response, cytogenetic response and disease progression. For subjects who achieve CR, marrow CR, or PR a confirmation bone marrow aspirate and biopsy should be obtained 4 to 8 weeks after documentation of CR, marrow CR, or PR.

13.3 **Week 16 End of Treatment**: Subjects will complete a response assessment within one week after their last administration of ruxolitinib. Subjects discontinuing study early should complete their end of treatment visit within two weeks after their last dose of investigational product. Physical exam, vital signs, concomitant medication, adverse event reporting, CBC, and blood chemistry and BM aspirate and biopsy with cytogenetic analysis will be performed.

13.4 **Continuation Phase**: After completing cycle 4 response assessments, responders may continue to receive ruxolitinib and the final week 16 dose in the absence of DLT or disease progression until marketing approval of ruxolitinib for CMML. Bone marrow biopsy and aspirate will be repeated after every 4 cycles (For subjects who achieve CR, marrow CR, or PR a confirmation bone marrow aspirate and biopsy should be obtained 4 to 8 weeks after documentation of CR, marrow CR, or PR). A CBC will be obtained and complete metabolic profile as per standard of care. The off treatment assessment should be done within a week off treatment.

13.5 **Off Treatment assessment**: includes best response achieved, date of first response, date of loss of response, reason for discontinuation.

13.6 **Off study evaluation**: include vital status, date of death/last contact, transformation to AML and the date of transformation to AML if applicable. This evaluation will be updated every 6 month for 2 years.
| Study Calendar | Pre-Study | Wk 1 | Wk 2 | Wk 3 | Wk 4 | Wk 5 | Wk 6 | Wk 7 | Wk 8 | Wk 9 | Wk 10 | Wk 11 | Wk 12 | Wk 13 | Wk 14 | Wk 15 | Wk 16 | Wk 17 | Weeks 18-48 (if response) Monthly visits | Off-Study or continue if responding as per previous weeks |
|----------------|-----------|------|------|------|------|------|------|------|------|------|-------|-------|-------|-------|-------|-------|-------|-------------------------------|-----------------------------|
| Ruxolitinib<sup>a</sup> | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| Informed consent | X | | | | | | | | | | | | | | | | | | | | |
| Demographics | X | | | | | | | | | | | | | | | | | | | | |
| Medical history | X | | | | | | | | | | | | | | | | | | | | |
| Physical exam | X | | | | | | | | | | | | | | | | | | | | |
| Vital signs | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| Height | X | | | | | | | | | | | | | | | | | | | | |
| Weight | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| Performance Status | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| Concurrent medication review | X | | | | | | | | | | | | | | | | | | | | |
| CBC w/diff, plt, | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| Retic Count | X | | | | | | | | | | | | | | | | | | | | |
| Serum chemistry<sup>b</sup> | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| INR, PT, and PTT | X | | | | | | | | | | | | | | | | | | | | |
| Adverse event evaluation | X | | | | | | | | | | | | | | | | | | | | |
| Bone marrow biopsy/aspirate<sup>d</sup> | X | | | | | | | | | | | | | | | | | | | | |
| B-HCG<sup>c</sup> | X | | | | | | | | | | | | | | | | | | | | |
| Lab. Correlates<sup>c</sup> | X | X | X | X | X | X | X | X | X | X | | | | | | | | | | | | | |

Adverse events will be summarized and reported prior to each cycle.
Prior CMML Treatments

Transfusion Log

Response Assessments

Symptom Score Scale

Off-treatment Assessment/Off-Study Follow-up/CMML Summary Form

<table>
<thead>
<tr>
<th>Prior CMML Treatments</th>
<th>X</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Transfusion Log</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Response Assessments</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Symptom Score Scale f</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Off-treatment Assessment/Off-Study Follow-up/CMML Summary Form</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a. Dose as assigned for cohort in phase 1, dose assigned as MTD in phase 2
b: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, potassium, total protein, AST, ALT, sodium, and total bilirubin.
c: Serum or urine pregnancy test (women of childbearing potential).
d: in addition to specimen required for pathologic review, and additional aspirate will be collected (goal volume of 30cc)
e: in addition to specimen required for routine labs, 6 green top vials, 1 red top vial; on week 1, peripheral blood will be collected twice: at time of first dose, and 3 hours after first dose.
f: The Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF) using ERT’s DiaryPro done by the patient. Data upload and device maintenance will occur at each scheduled visit.

**Week 16 Evaluation and End of Treatment:** Subjects will complete a response assessment within one week after their last administration of ruxolitinib. Subjects discontinuing study early should complete their end of treatment visit within two weeks after their last dose of investigational product. Physical exam, vital signs, concomitant medication, adverse event reporting, CBC, and blood chemistry and BM aspirate and biopsy with cytogenetic analysis will be performed.

**Continuation Phase:** After completing cycle 4 response assessments, HI-platelet responders may continue to receive ruxolitinib and the final week 16 dose in the absence of DLT or disease progression until marketing approval of ruxolitinib for CMML. Bone marrow biopsy and aspirate will be repeated after every 4 cycles. A CBC will be obtained and complete metabolic profile as per standard of care. The off treatment assessment should be done within a week off treatment.

*** For subjects who achieve CR, marrow CR, or PR a confirmation bone marrow aspirate and biopsy should be obtained 4 to 8 weeks after documentation of CR, marrow CR, or PR.

Off Treatment assessment: includes best response, date of first response, date of loss of response, reason for discontinuation.

Off study follow up: include vital status, date of death/last contact, transformation to AML and the date of transformation to AML if applicable. This evaluation will be updated every 6 month for 2 years.

**** all dates are +/- one week
14 MEASUREMENT OF EFFECT

Definitions:
Response and progression will be assessed according to modified International Working Group (IWG) 2006 criteria\(^2\) (Appendix B). Improvements must last ≥ 8 weeks.

- **Erythroid Response** for pretreatment hemoglobin < 11 g/dl:
  
  ≥ 1.5 g/dL increase in hemoglobin.

  For transfused subjects having pre-transfusion baseline hemoglobin ≤ 9 g/dL, a reduction of 4 or more RBC units in the previous 8 weeks compared with pretreatment.

- **Platelet response** for subjects with a pre-treatment platelet count < 50 \(\times\) 10\(^9\)/L:
  - **Major platelet response**: An absolute increase of ≥ 30 \(\times\) 10\(^9\)/L. If platelets are < 20 \(\times\) 10\(^9\)/L at baseline, then a 100% increase will qualify as a major platelet response. If subjects are transfusion dependent at baseline, platelet transfusion independence sustained for 8 consecutive weeks will qualify as a major platelet response.
  - **Complete platelet response**: increase of platelet count to ≥ 100 \(\times\) 10\(^9\)/L for 8 consecutive weeks.

- **Neutrophil response** with pretreatment ANC < 1 \(\times\) 10\(^9\)/L:
  
  ≥ 100% increase and an absolute increase of > 0.5 \(\times\) 10\(^9\)/L

  Progression/relapse following hematological improvement: At least one of the following:
  
  - Any newly developed (RBC/platelet) transfusion dependence,
  - ≥ 50% decrease from maximum response levels in granulocytes or platelets, or
  - Reduction of ≥ 1.5 g/dL hemoglobin.

- **Complete Response (CR)**
  
  Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines

  Persistent dysplasia will be noted

  Peripheral blood:

  - Hemoglobin ≥ 11 g/dL
  - Platelets ≥ 100 \(\times\) 10\(^9\)/L
  - Neutrophils ≥ 1.0 \(\times\) 10\(^9\)/L
  - BLASTS <0%

- **Partial Response (PR)**
  
  All CR criteria if abnormal before treatment, except:

  Bone marrow blasts decreased by ≥ 50% over pretreatment but still > 5%

  **Cellularity and morphology not relevant**

- **Marrow Complete Response (mCR)**
  
  Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment

  **Peripheral blood**: if HI responses, they will be noted in addition to marrow CR
Stable Disease (SD)
Failure to achieve at least PR, but no evidence of progression for > 8 weeks

Duration of Response:
The duration of response is measured from the time measurement criteria are met for major or complete platelet response (which ever is first recorded) until the first date that disease progression defined by the bone marrow response outlined above, progression/relapse following a CR, marrow CR or PR, or progressions/relapse following hematological improvement (HI) as outlined above.

Pathologic Response: Pathologic response is categorized as a CR, mCR or a PR. Response parameters in the peripheral blood and/or bone marrow must be sustained for at least 4 weeks. See appendix B.

Symptom Assessment in CMML
Symptoms of CMML will be assessed using the MPN-SAF (see Appendix D). Subjects will be issued a hand-held device (eDiary) on which to record symptoms of CMML. The subject will be instructed to complete the eDiary each night beginning on Day -4 or earlier of the screening phase (eg, 4 days prior to Cycle 1 Day 1) through treatment discontinuation. Subjects will bring the device to the study site at each study visit so that the device charging can be verified and accumulated data can be downloaded, as applicable. The device will then be returned to the subject at these same visits for continued use each night. The subject will return the device and the docking station for the final time at the EOT visit so that the data can be archived. Detailed directions for the administration of the eDiary will be provided in the Study Reference Manual.

15 STATISTICAL CONSIDERATIONS

15.1 Study Design
This is a phase 1/2, two-stage, sequential cohort dose escalation study. In phase 1, subjects will be allocated to dose levels starting at 10 mg/d (BID dosing) according to the “rolling six” phase I design (see Section 6.2 for the definition of DLT and the dose levels employed and Section 6.4 for the dose escalation
schema). Enrollment to the next dose level will be as per the dose escalation rules table (6.4.1). Subjects who do not complete the first cycles of protocol treatment and drop out of the trial due to any reason other than experiencing a DLT will have to be replaced in order to determine a proper MTD. Phase 1 will continue until MTD is reached. The Phase 2, two-stage, study will enroll a total of 29 patients to determine overall best response at the MTD.

15.2 Sample Size/Accrual Rate
If dose escalation is completed as planned, no more than 53 subjects are expected to enroll onto this study at a rate of approximately 3 subjects every month. For the Phase 2 study the Simon’s optimal two-stage design will be employed to test the null hypothesis that response rate (RR) equals to 10% versus the alternative that RR equals to 30%. If the treatment is actually not effective, there is a 0.05 probability of concluding that it is. If the drug is actually effective, there is a 0.19 probability of concluding that it is not. The probability of early terminating the trial at the end of first stage under the null is 0.74. After testing the treatment dose on 10 patients in the first stage, the trial will be terminated if 1 or fewer desired respond. If the trial goes on to the second stage, a total of 29 patients will be studied. If the total number responding is less than or equal to 5, the drug is rejected. A sample size of 29 from Phase 2 produces a two-sided 95% CI with a width equal to 0.38 (±19) when the sample proportion is 0.50 that is the maximum width for a CI with an given sample sizes.

15.3 Statistical Analysis Methods
Demographic and clinical variables for the study patients will be summarized using descriptive statistics (mean, standard deviation, median, inter-quartile range, range, and frequency counts and percentages). Safety and efficacy data will be analyzed overall as well as separately for each dose cohort when appropriate.

15.4 Safety Analysis
This analysis will include all subjects who have received any protocol treatment, regardless of patient eligibility. The number (%) of subjects with adverse events, serious adverse events, and adverse events leading to treatment discontinuation will be reported. Adverse events summary will be reported by type and severity.
Laboratory parameters will also be summarized using descriptive statistics. The number and proportion of subjects with DLTs will be summarized.

15.5 Efficacy Analysis: ITT

This analysis will include all subjects who have received any protocol treatment, regardless of patient eligibility or duration of treatment. Those who have no response assessment data due to reasons such as drop out of the study, withdrawal consent, or lost to follow-up will be treated as non-responders for various response evaluations. The proportion of subjects achieving a complete platelet response will be summarized. A 95% exact binomial confidence interval of the proportion will also be provided for all participants treated at the MTD. In addition, a second analysis of evaluable subjects will be performed. Evaluable subjects are defined as those who complete at least 8 weeks of therapy and complete their first treatment bone marrow biopsy and aspirate to evaluate study drug response.

15.6 Analyses of Secondary Endpoints

**Analyses of the following secondary endpoints will be performed as well:**

15.6.1 Acute myeloid leukemia (AML) transformation according to WHO criteria.

15.6.2 Overall survival (OS).

15.6.3 Duration of response.

15.6.4 The Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF) at baseline and at best response.

15.6.5 >50% decrease in splenic length as measured by physical exam if applicable

15.6.6 The suppression of pSTAT5 intracellular signaling after ruxolitinib in CMML subjects (pretreatment, at 1-2hr post treatment, cycle 2, cycle 4, and progression.)

15.6.7 Determine number of colonies formed in the presence of GM-CSF and/or ruxolitinib (pretreatment and progression) as a future predictor of response.

15.6.8 Mutational status in our CMML subjects by sanger sequencing of JAK2, c-CBL, N-RAS, K-RAS, RUNX-1, TET2, SRSF2, EZH2, ASXL1, and DNMT3a (pretreatment and progression).

15.6.9 Mutational status of JAK2 tyrosine kinase at time of progression by deep sequencing of JAK2 to include M929I, Y931C, G935R, R938L, I960V, E985K.
We recognize that this is mainly a phase I study with an extension phase at the MTD. However, preliminary data on the above endpoints will prove to be very useful for further investigation of this protocol’s treatment. Such data will be summarized appropriately focusing mostly on the subjects treated at the MTD dose in an exploratory fashion. Both point estimates and 95% confidence intervals will be reported, if feasible. Time-to-event endpoints such as OS will be summarized using the Kaplan-Meier product-limit method.

16 Laboratory Correlates
Unless otherwise specified, all laboratory correlates will be performed in the laboratory of P.K. Epling-Burnette under the direction of Drs Burnette and Padron.

H. LEE MOFFITT CANCER CENTER
CC: ERIC PADRON
STABILE RESEARCH BUILDING
SRB-2
12902 MAGNOLIA DR TAMPA FL 33612

16.1 Sample Collection

At Screening and weeks 1, 5, 9, 13, and 17 (see study calendar), peripheral blood will be collected. Designated study personnel will collect the sample from the laboratory draw area. Peripheral blood will be collected in six green top (heparinized) 10cc tubes and one red top (clot activator or no additive) 10cc tube for a total of seven tubes and 70cc of peripheral blood. At the time of the first dose, peripheral blood will be collected twice: once at the time of the first dose (or up to one hour prior to the first dose) in six green top 10cc tubes and one red top 10cc tube, and again three hours after the first dose (+/- 30 minutes) in six green top 10cc tubes and one red top 10cc tube, for a total of 14 tubes and 140cc of peripheral blood. At Screening and weeks 8 and 16 (see study calendar), bone marrow aspirate will be collected in three lavender (EDTA) 10cc tubes for a total of 30cc. These will be shipped to the H. Lee Moffitt Cancer Center laboratory as directed above within 24hrs and will be processed first by centrifugation (730 rcf for 5 minutes) to collect the supernatant (plasma from green top or lavender top;
serum from red top). Green top and lavender top samples will be additionally processed by centrifugation (530 rcf for 20 minutes) with density gradient medium to collect the mononuclear cellular layer, followed by the addition of RBC lysis buffer to remove RBCs and debris. The mononuclear cells will be cryopreserved as previously described and stored in liquid nitrogen for later use labeled with a unique identifier that corresponds to each patient known only to the investigator and study personnel. The plasma and serum will be cryopreserved for later use labeled with a unique identifier that corresponds to each patient known only to the investigator and study personnel.

16.2 pSTAT5 as a pharmacodynamic marker for ruxolitinib.

At the time of the first dose the subjects’ (may be up to one hour prior to first dose) peripheral blood will be collected, processed and stored as above. Peripheral blood will again be drawn three hours after the first dose (+/- 30 minutes) and be collected, processed and stored as above. Peripheral blood will also be collected at the assigned time points (see study calendar) and processed as above. These samples will be batched for analysis after 10 samples have been processed and cryopreserved. They will be reconstituted in STEM span and 20% FBS in the laboratory of P.K. Epling-Burnette. pSTAT5 will be measured using phos-flow cytometry as previously described at baseline, after one hour of serum free condition, and then stimulated with 0.1, 1, and 10 ng/ml of GM-CSF. The in vitro efficacy of ruxolitinib will also be evaluated by the addition of increasing doses of ruxolitinib and measurement pSTAT5 as above.

16.3 In vitro hematopoietic colony formation

Bone marrow aspirates will be collected as per the study calendar (page 36). Mononuclear cells from frozen aspirate from CMML subjects will be plated in methylcellulose for 14 days. Experimental Conditions will include no cytokine, GM-CSF, and with or without increasing doses of ruxolitinib. Colonies will be counted after 14 day and experimental conditions will be compared to evaluate ruxolitinib efficacy. The colony formation assay described remains the gold standard for in vitro differentiation and proliferation experiments in hematopoietic precursors. Our laboratory has been able to plate previously frozen cells with
GM-CSF inhibitors and detect differences in colony numbers. The vast majority of colonies detected in our preliminary data are of the GM-CFU type with an occasional GEMM-CFU colony. Our colony “read out” is defined as any hematopoietic cluster of greater than 50 cells regardless of morphology. It is anticipated that ruxolitinib will decrease colony formation in a dose dependent fashion and perhaps predict for \textit{in vivo} efficacy.

16.4 \textbf{Genomic Studies}

Using portion of cryopreserved bone marrow aspirates, 100ug of DNA will be isolated as previously described. Next, a comprehensive sequencing of subjects by NextGen sequencing of JAK2, c-CBL, N-RAS, K-RAS, RUNX-1, TET2, SRSF2, EZH2, ASXL1, and DNMT3a will be done in with pretreatment samples and end of study or progression. The isolated DNA will be sent to the laboratory of Dr. Omar Abdel-Waheb located on the campus of Memorial Sloan Kettering Cancer Center. Dr Abdel-Waheb has is a nationally recognized expert in the genomics of myeloid malignancies and has sequenced many patients for this comprehensive panel of gene mutations.

16.5 \textbf{JAK2 mutations as a mechanism of Ruxolitinib resistance}

Mutational status of JAK2 tyrosine kinase at time of progression by deep sequencing of JAK2 at pretreatment and at progression to include M929I, Y931C, G935R, R938L, I960V, E985K. Emerging reports have suggested mutations in JAK2 that may confer resistance to ruxolitinib. We will use samples from subjects taken at the above time, isolate DNA as previously described and amplify the JAK2 transcript by PCR. Next, gel extraction will be done and the entire JAK2 coding region will be sequenced at the H. Lee Moffitt Cancer Center molecular genomics core.

17 \textbf{REGULATORY CONSIDERATIONS}

This research will be done in compliance with the applicable State and Federal laws and regulations and in compliance with ICH guidelines. The study description will be posted on the \url{www.clinicaltrials.gov} website in compliance with current regulations. The data and safety plan will be executed in accordance with ICH guidelines and in compliance with policy and procedures at the H. Lee Moffitt Cancer Center and Research Institute. The
following must be observed to comply with Food and Drug Administration regulations for the conduct and monitoring of clinical investigations; they also represent sound research practice:

17.1 Informed Consent

The principles of informed consent are described by Federal Regulatory Guidelines (Federal Register Vol. 46, No. 17, January 27, 1981, part 50) and the Office for Protection from Research Risks Reports: Protection of Human Subjects (Code of Federal Regulations 45 CFR 46). They must be followed to comply with FDA regulations for the conduct and monitoring of clinical investigations.

17.2 Use of Specimens For Research

The patient is free at any time in the future to decide not to provide specimens or to withdraw his/her specimens from further scientific research. Such a decision will have no impact on his/her treatment or other aspects of participation in this study.

17.3 Institutional Review

This study must be approved by an appropriate institutional review committee as defined by Federal Regulatory Guidelines (Ref. Federal Register Vol. 46, No. 17, January 27, 1981, part 56) and the Office for Protection from Research Risks Reports: Protection of Human Subjects (Code of Federal Regulations 45 CFR 46).

17.4 Drug Accountability

For each drug supplied for a study, an accountability ledger containing current and accurate inventory records covering receipt, dispensing, and the return of study drug supplies must be maintained. Drug supplies must be kept in a secure, limited access storage area under the recommended storage conditions. During the course of the study, the following information must be noted on the accountability ledger; the identification code of the subject to whom drug is dispensed, the date(s) and quantity of drug dispensed to the subject, and the date(s) and quantity of drug returned by the subject; subjects should return empty containers to the investigator, with the return noted on the ledger. These Accountability Forms must be readily available for inspection and are open to FDA inspection at any time.

17.5 RETENTION OF RECORDS

U.S. FDA regulations (21 CFR §312.62[c]) require that records and documents pertaining to the conduct of this study and the distribution of investigational drug,
including CRFs, consent forms, laboratory test results, and medication inventory records, must be retained by the Principal Investigator for 2 years after marketing application approval. If no application is filed, these records must be kept 2 years after the study is discontinued and the U.S. FDA and the applicable national and local health authorities are notified.

17.6 Study Monitoring:
As part of the responsibilities assumed by participating in the study, the Investigator agrees to maintain and have available for monitoring adequate case records (accurate source documents and CRFs) for the subjects treated under this protocol. In addition, the Investigator agrees to maintain all administrative documents, eg, IRB/IEC correspondence, investigational product and supplies shipment manifests, monitoring logs, or Moffitt Cancer Center/designee correspondence. The PI will be primarily responsible for monitoring of adverse events, protocol violations, and other immediate protocol issues. The study coordinator will collect information of subjects enrolled at Moffitt and other institutions through the use of electronic or paper AE forms, CRF forms, End of Study forms, and Informed Consent forms.

Internal Monitoring
Data will be captured in Oncore, Moffitt’s Clinical Trials Database. The Case Report Forms will be reviewed by Moffitt’s Internal Monitors, periodically, throughout the conduct of the trial. The monitoring will include source data verification, utilizing research subjects’ medical records.

On-site Audits
The Investigator should promptly notify Moffitt Cancer Center or its authorized representative of any audits scheduled by any regulatory authorities and promptly forward copies of any audit reports received to Moffitt Cancer Center or its authorized representative.

Data & Safety Monitoring Plan
Identification of oversight responsibility:
The PI has primary responsibility.
The MCC Protocol Monitoring Committee (PMC);
The PMC meets monthly and reviews accrual, patterns and frequencies of all adverse
events, protocol violations and when applicable, internal audit results.

**Description of internal (PI) safety review and monitoring process:**

Responsible for identifying and reviewing adverse events biweekly:

Principal Investigator

Study team

**To be reviewed:**

Adverse events by grade (Gr. 3 or above using CTCAE v4.0) and attribution (expected or unexpected)

Relationship to study drug/intervention

Application of dose finding escalation/de-escalation rules

Application of study designed stopping/decision rules

Whether the study accrual pattern warrants continuation/action

Protocol violations

AEs will be reported along with all other data in the Oncore database. The PI or PI designate will report all adverse events to the Clinical Research Office (CRO). The CRO will report all SAEs to INCYTE, and all reportable SAEs to the IRB. AE information will be entered into the CRO database. AE information will be managed by the CRO and will be made available to the PMC or appropriate monitoring body by designated members of the PMC or the study statisticians.

18 REFERENCES


Performance Status Criteria

<table>
<thead>
<tr>
<th>Grade</th>
<th>ECOG Performance Status Scale</th>
<th>Percent</th>
<th>Karnofsky Performance Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal activity. Fully active, able to carry on all pre-disease</td>
<td>100</td>
<td>Normal, no complaints, no evidence of disease.</td>
</tr>
<tr>
<td></td>
<td>performance without restriction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Symptoms, but ambulatory. Restricted in physically strenuous activity,</td>
<td>80</td>
<td>Able to carry on normal activity; minor signs or</td>
</tr>
<tr>
<td></td>
<td>but ambulatory and able to carry out work of a light or sedentary</td>
<td></td>
<td>symptoms of disease.</td>
</tr>
<tr>
<td></td>
<td>nature (e.g., light housework, office work).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>In bed &lt;50% of the time. Ambulatory and capable of all self-care, but</td>
<td>60</td>
<td>Normal activity with effort; some signs or symptoms of</td>
</tr>
<tr>
<td></td>
<td>unable to carry out any work activities. Up and about more than 50%</td>
<td></td>
<td>disease.</td>
</tr>
<tr>
<td></td>
<td>of waking hours.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>In bed &gt;50% of the time. Capable of only limited self-care, confined</td>
<td>40</td>
<td>Requires occasional assistance, but is able to care for</td>
</tr>
<tr>
<td></td>
<td>to bed or chair more than 50% of waking hours.</td>
<td></td>
<td>most of his/her needs.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>30</td>
<td>Requires considerable assistance and frequent medical</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>care.</td>
</tr>
<tr>
<td>4</td>
<td>100% bedridden. Completely disabled. Cannot carry on any self-care.</td>
<td>20</td>
<td>Disabled, requires special care and assistance.</td>
</tr>
<tr>
<td></td>
<td>Totally confined to bed or chair.</td>
<td></td>
<td>Severely disabled, hospitalization indicated. Death not</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td>imminent.</td>
</tr>
<tr>
<td>5</td>
<td>Dead.</td>
<td>0</td>
<td>Dead.</td>
</tr>
</tbody>
</table>
### APPENDIX B

RESPONSE CRITERIA FOR SUBJECTS WITH CMML ACCORDING IWG 2006

<table>
<thead>
<tr>
<th>CRITERIA</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALTERING DISEASE NATURAL HISTORY</strong></td>
<td></td>
</tr>
<tr>
<td>Complete remission (CR)</td>
<td>Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines&lt;br&gt;Persistent dysplasia will be noted&lt;br&gt;Peripheral blood:&lt;br&gt;  - Hemoglobin ≥ 11 g/dL&lt;br&gt;  - Platelets ≥ 100 x 10^9/L&lt;br&gt;  - Neutrophils ≥ 1.0 x 10^9/L&lt;br&gt;  - Blasts 0%</td>
</tr>
<tr>
<td>Partial remission (PR)</td>
<td>All CR criteria if abnormal before treatment, except:&lt;br&gt;  - Bone marrow blasts decreased by ≥ 50% over pretreatment but still &gt; 5%&lt;br&gt;  - Cellularity and morphology not relevant</td>
</tr>
<tr>
<td>Marrow CR</td>
<td>Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment&lt;br&gt;Peripheral blood: if HI responses, they will be noted in addition to marrow CR</td>
</tr>
<tr>
<td>Stable disease (SD)</td>
<td>Failure to achieve at least PR, but no evidence of progression for &gt; 8 weeks</td>
</tr>
<tr>
<td>Failure</td>
<td>Death during treatment&lt;br&gt;Disease progression characterized by worsening of cytopenias, increase in % of bone marrow blasts, or progression to a more advanced MDS FAB subtype than pretreatment</td>
</tr>
<tr>
<td>Disease Progression (PD)</td>
<td>For subjects with:&lt;br&gt;  - Less than 5% blasts: ≥ 50% increase in blasts to &gt; 5% blasts&lt;br&gt;  - 5%-10% blasts: ≥ 50% increase in blasts to &gt; 10% blasts&lt;br&gt;  - 10%-20% blasts: ≥ 50% increase in blasts to &gt; 20% blasts&lt;br&gt;  - 20%-30% blasts: ≥ 50% increase in blasts to &gt; 30% blasts&lt;br&gt;Any of the following:&lt;br&gt;  - At least 50% decrement from maximum remission/response levels in granulocytes or platelets&lt;br&gt;  - Reduction in hemoglobin (Hgb) concentration by ≥ 2 g/dL</td>
</tr>
</tbody>
</table>

| CYTOGENETIC RESPONSE | |
| Complete | Disappearance of the chromosomal abnormality without appearance of new ones |
| Partial | At least 50% reduction of the chromosomal abnormality |

| HEMATOLOGICAL IMPROVEMENT (HI) | |
| Erythroid response (HI-E) (Pretreatment < 11 g/dL) | Hgb increase by ≥ 1.5 g/dL<br>Relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 weeks compared with the pretreatment transfusion number in the previous 8 weeks. Only RBC transfusions given for a Hgb of ≤ 9.0 g/dL pretreatment will count in the RBC transfusion evaluation |
| Platelet response (HI-P) (Pretreatment < 100 x 10^9/L) | Absolute increase of ≥ 30 x 10^9/L for subjects starting with > 20 x 10^9/L<br>Increase from < 20 x 10^9/L to ≥ 20 x 10^9/L and by at least 100% |
| Neutrophil response (HI-N) (Pretreatment < 1.0 x 10^9/L) | At least 100% increase and an absolute increase of > 0.5 x 10^9/L |
## PROGRESSION/RELAPSE CRITERIA FOR SUBJECTS WITH CMML

### ALTERING DISEASE NATURAL HISTORY

<table>
<thead>
<tr>
<th>Disease Progression (PD)</th>
<th>For subjects with:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Less than 5% blasts: ≥ 50% increase in blasts to &gt; 5% blasts</td>
</tr>
<tr>
<td></td>
<td>5%-10% blasts: ≥ 50% increase in blasts to &gt; 10% blasts</td>
</tr>
<tr>
<td></td>
<td>10%-20% blasts: ≥ 50% increase in blasts to &gt; 20% blasts</td>
</tr>
<tr>
<td></td>
<td>20%-30% blasts: ≥ 50% increase in blasts to &gt; 30% blasts</td>
</tr>
<tr>
<td></td>
<td>Any of the following:</td>
</tr>
<tr>
<td></td>
<td>At least 50% decrement from maximum remission/response levels in granulocytes or platelets</td>
</tr>
<tr>
<td></td>
<td>Reduction in hemoglobin (Hgb) concentration by ≥ 2 g/dL</td>
</tr>
<tr>
<td></td>
<td>Transfusion dependence</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disease transformation</th>
<th>Transformation to AML (30% or more blasts)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Relapse after CR or PR</th>
<th>At least one of the following:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Return to pretreatment bone marrow blast %</td>
</tr>
<tr>
<td></td>
<td>Decrement of ≥ 50% from maximum remission/response levels in granulocytes or platelets</td>
</tr>
<tr>
<td></td>
<td>Reduction in Hgb concentration by ≥ 1.5 g/dL or transfusion dependence</td>
</tr>
</tbody>
</table>

### HEMATOLOGICAL IMPROVEMENT

<table>
<thead>
<tr>
<th>Progression/relapse after HI</th>
<th>At least one of the following:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>At least 50% decrement from maximum response levels in granulocytes or platelets</td>
</tr>
<tr>
<td></td>
<td>Reduction in Hgb by ≥ 1.5 g/dL</td>
</tr>
<tr>
<td></td>
<td>Transfusion dependence</td>
</tr>
</tbody>
</table>
21 APPENDIX C: CYP3A4 Strong Inhibitors

**HIV Antivirals:**
- indinavir
- boceprevir
- lopinavir/ritonavir
- ritonavir
- telaprevir
- nelfinavir
- saquinavir

**Others:**
- clarithromycin
- conivaptan
- grapefruit juice
- mibefradil
- posaconazole
- voriconazole
- itraconazole
- ketoconazole
- nefazodone
- telithromycin

* Dose reductions as in section 7 are required for strong inhibitors of the CYP3A4.
The Myelofibrosis Symptom Assessment Form (MPN-SAF) Validation Survey.

**Instructions:** Please fill out all questions, as best able, until the STOP instruction toward the end of the packet.

**Brief Fatigue Inventory ©**

**Instructions:** Please fill out all questions, as best able, reflecting how these symptoms affected you over the **LAST WEEK** unless directed otherwise. Complete forms until the STOP instruction toward the end of the packet.

<table>
<thead>
<tr>
<th>Symptom</th>
<th>1 to 10 (0 if absent) ranking*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your fatigue right NOW</td>
<td>(No Fatigue) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your USUAL level of fatigue during past 24 hours</td>
<td>(No Fatigue) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your WORST level of fatigue during past 24 hours</td>
<td>(No Fatigue) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
</tbody>
</table>

Circle the one number that describes how, during the past 24 hours, fatigue has interfered with your

- General activity          (Does not Interfere) 0 1 2 3 4 5 6 7 8 9 10 (Completely Interferes)
- Mood                     (Does not Interfere) 0 1 2 3 4 5 6 7 8 9 10 (Completely Interferes)
- Walking ability          (Does not Interfere) 0 1 2 3 4 5 6 7 8 9 10 (Completely Interferes)
- Normal work (includes work both outside the home and daily chores) (Does not Interfere) 0 1 2 3 4 5 6 7 8 9 10 (Completely Interferes)
- Relations with other people (Does not Interfere) 0 1 2 3 4 5 6 7 8 9 10 (Completely Interferes)
- Enjoyment of life        (Does not Interfere) 0 1 2 3 4 5 6 7 8 9 10 (Completely Interferes)

© MD Anderson Cancer Center
# Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)

Circle the one number that describes how, during the past week, how much difficulty you have had with each of the following symptoms:

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filling up quickly when you eat (Early satiety)</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Abdominal discomfort</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Inactivity</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Problems with headaches</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Problems with concentration - Compared to prior to my MPD</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Dizziness/Vertigo/Lightheadedness</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Numbness/Tingling in my hands and feet</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Difficulty sleeping</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Depression or sad mood</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Problems with sexual desire or Function</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Cough</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Night sweats</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Itching (pruritus)</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Bone pain (diffuse not joint pain or arthritis)</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>Fever (&gt;100 F)</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Daily)</td>
</tr>
<tr>
<td>Unintentional weight loss last 6 months</td>
<td>0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)</td>
</tr>
<tr>
<td>What is your overall quality of life?</td>
<td>(As good as it can be) 0 1 2 3 4 5 6 7 8 9 10 (As bad as it can be)</td>
</tr>
</tbody>
</table>

© Mayo Clinic
## APPENDIX E: WHO CLASSIFICATION FOR CMML

<table>
<thead>
<tr>
<th>WHO Subtype</th>
<th>Peripheral Blood</th>
<th>Bone Marrow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic Myelomonocytic Leukemia *CMML-1 **CMML-2</td>
<td>*&lt;5 percent blasts **&lt;19 percent blasts **&lt;19 percent blasts  persistent monocytosis &gt;1000/ul +/- cytopenias Leukocytosis frequent</td>
<td>*&lt;10% myeloblast **&lt;19 percent blasts &gt;10% dysplasia in affected lineage **Auer Rods The absence of the Philadelphia chromosome of bcr-abl fusion gene.</td>
</tr>
</tbody>
</table>